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AbsTrACT
Introduction Increasing numbers of children and 
young people (CYP) are receiving prescriptions for 
antidepressants. This is the protocol of a study aiming 
to describe the trends and variation in antidepressant 
prescriptions in CYP in England, and to examine the 
indications for the prescriptions recorded and whether 
there was contact with secondary care specialists on or 
around the time of the first antidepressant prescription.
Methods and analysis All eligible CYP aged between 
5 and 17 years in 1998–2017 from the QResearch 
primary care database will be included. Incidence and 
prevalence rates of any antidepressant prescription 
in each year will be calculated. We will examine four 
different antidepressant classes: selective serotonin 
reuptake inhibitors, tricyclic and related antidepressants, 
serotonin and norepinephrine reuptake inhibitors and 
other antidepressants, as well as for individual drugs. 
Linked primary and secondary care data (hospital episode 
statistics) in the year before and up to 6 months after 
the first antidepressant prescription will be examined 
for CYP whose first antidepressant prescription was in 
2006–2017. Whether there were records of indications 
and being seen by psychiatric or paediatric specialists 
will be identified. Trends over time and differences by 
region, deprivation and ethnicity will be examined using 
Poisson regression.
Discussion This large, population-based study will 
give an up-to-date picture of antidepressant prescribing 
in CYP and identify any variation. Understanding what 
indications are recorded when CYP are being prescribed 
antidepressants, and whether this was done in 
partnership with secondary care specialists, will provide 
evidence of whether appropriate guidelines are being 
followed.
InTroDuCTIon
In a UK 2017 national survey,1 the estimated 
proportions of children and young people (CYP) 
in England with depressive disorders were 0.3% of 
5–10 year-olds, 2.7% of 11–16 year-olds and 4.8% 
of 17–19 year-olds. These figures reflect around 
200 000 affected 5–19 year-olds.2 The propor-
tion of 5–15 year-olds with depressive disorders 
in England was estimated to have increased from 
0.9% in 1999 and 0.8% in 2004 to 1.2% in 2017. 
Recording of depression symptoms rather than 
diagnoses is higher, and reported by 24% of girls 
and 9% of boys aged 14 in the UK-based Millen-
nium Cohort Study.3 Compared with adults, chil-
dren and adolescents with major depressive disorder 
are still underdiagnosed and undertreated,4 possibly 
because they tend to present with rather undiffer-
entiated depressive symptoms, for example, irri-
tability, aggressive behaviours or school refusal.5 
Consequences of depressive episodes in these young 
people include serious impairments in social func-
tioning, as well as suicidal ideation and attempts.6 
Although psychological treatments are consid-
ered the first-line treatment in many clinical guide-
lines including the UK The National Institute for 
Health and Care Excellence (NICE) guidelines,6 
antidepressants are widely used in the treatment 
of depression in children and adolescents, and in 
the past few decades prescription of antidepressants 
in young people has increased significantly both in 
the UK7–9 and in other countries.10 However, even 
though antidepressants in combination with psycho-
logical therapy is recommended for moderate to 
severe depression in the NICE guideline (CG28) 
for depression in CYP,11 the efficacy and safety of 
antidepressant medicines remain controversial.12 13 
In line with these recommendations and based on 
results of meta-analyses,13 the only first-line anti-
depressant recommended for CYP with moderate 
to severe depression is fluoxetine initiated in 
secondary care following assessment and diagnosis 
by a child and adolescent psychiatrist.6 Sertraline 
and citalopram are recommended by NICE as 
second-line antidepressants in particular circum-
stances if fluoxetine is not tolerated or unsuc-
cessful.11 Some antidepressants can be prescribed 
to CYP with obsessive-compulsive disorder (along-
side psychological treatments)14 or for other condi-
tions,15 including unlicensed ‘off-label’ use, such as 
for neuropathic pain.16
Studies have shown a pattern of increasing anti-
depressant prescription rates in CYP in the UK, 
up to 2009,7 2011,8 201317 and 2015.9 Rates of 
depression symptom recording have increased 
while recorded diagnoses of depression have 
decreased over the same periods.17 This pattern of 
symptoms rather than diagnoses being recorded is 
demonstrated by previous work in the UK finding 
only 24% of those first prescribed antidepressants 
had a depression diagnosis within the previous 
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year to 4 weeks after the first prescription,9 while another study 
showed over half had either a depression diagnosis or depression 
symptoms recorded in the year before to 6 months after their 
prescription.17
So far, there has been little research into variation in anti-
depressant prescribing, particularly in CYP. Recent evidence 
shows that rates of antidepressant prescriptions in England in 
2015/2016 were lowest in London, and highest in the North 
East.18 Studies have shown that children and adolescents7 17 and 
adults18 residing in the most deprived quintiles were more likely 
to receive antidepressant prescriptions compared with those in 
the least deprived quintile in the UK.
Surveys found that Black, South Asian and Mixed/other 
ethnic groups were less likely to have received antidepressants 
than the White group.19 Within areas of London, antidepres-
sant use was highest in the White British group (8.1%), almost 
half this rate in Bangladeshis (4.4%) and the lowest rate was 
in the Indian and Black African groups (2.1%).20 While these 
studies used self-assigned person-level ethnicity, others have 
used different measures of ethnicity. A study using the propor-
tion of Asian names on general practitioner (GP)'s practice 
lists found antidepressant prescribing was higher in practices 
with low proportions of Asians on the list,21 and another 
showed antidepressant prescription volumes were lower in 
GP practices with high densities of Black and South Asian 
populations.22
The present study provides an opportunity to examine vari-
ation in antidepressant prescriptions in CYP by deprivation, 
region and ethnicity simultaneously in a large population from 
England, over a 20-year period. This will allow any inequalities 
to be identified, and enable future studies to determine whether 
these are due to differences in need or due to inequity, where any 
differences are avoidable and unfair.
Our study aims to (1) examine changes over time and varia-
tion in antidepressant prescribing in CYP aged between 5 and 
17 years old between 1998 and 2017, (2) investigate the clin-
ical indications associated with these prescriptions recorded in 
primary and secondary care data and (3) assess adherence with 
NICE guideline recommendations.
Our objectives are as follows:
 ► To describe differences in antidepressant prescribing over 
time by age, sex, region, deprivation and ethnicity.
 ► To compare patterns of antidepressant prescribing against 
NICE guideline recommendations for the management of 
depression in CYP to determine whether fluoxetine is used 
as a first-line treatment.
 ► To determine whether those with antidepressant prescrip-
tions have the appropriate clinical indications recorded in 
primary or secondary care records.
 ► To examine admitted patient care and outpatient hospital 
episode statistics (HES) data to identify whether CYP had 
been assessed in secondary care by a child and adolescent 
psychiatrist (as recommended by NICE CG28) at the time of 
initiation of antidepressant prescribing.
MeThoDs AnD AnAlysIs
Patient and public involvement
This work is part of the National Institute for Health Research 
Nottingham BRC Mental Health & Technology theme looking 
at decision aid tools and risk assessment. Patient and public 
involvement (PPI) representatives are part of this research 
team, attending monthly project meetings and additional, more 
frequent, meetings focusing on PPI aspects of the project.
study design and data sources
We will examine incidence and prevalence of antidepressant 
prescribing in a cohort of CYP in England using a large primary 
care database (QResearch, version 43) linked to HES admitted 
patient care and outpatient data. At the time of the study, the 
QResearch database includes health records of over 32 million 
people from more than 1500 general practices across the UK 
which record data using the Egton Medical Information Systems 
(EMIS) medical records computer system. The information 
recorded includes personal characteristics, clinical diagnoses, 
symptoms and prescribed medicines.
The study cohort will include people who were aged between 
5 and 17 years between 1 January 1998 and 31 December 
2017. Each person’s study entry date is defined as the latest 
date of 12 months after their registration with a study practice, 
12 months after the installation date of their practice’s EMIS 
computer system, 1 January of the year they turned 5 years old 
or 1 January 1998. People will then be followed up until the 
earliest date of them leaving the practice, dying, 1 January of the 
year they turned 18 years old or the end of the follow-up period 
(31 May 2018).
We will examine trends separately for males and females, as 
defined in their primary care data. Overall trends will be exam-
ined for those aged 5–11 and 12–17 years—similar to the age 
groups specified in the NICE guidelines on depression in chil-
dren and young people, 11 but excluding 18-year-olds who may 
have been treated as adults. We will also study trends over time 
for different regions of England, Townsend deprivation quin-
tiles and ethnic groups. Where ethnicity information is missing 
in QResearch, we will supplement this with the most recent valid 
ethnic code available in HES. We will examine the five broad 
ethnic groups as used in the England and Wales 2001 Census: 
White, Mixed, Asian or Asian British, Black or Black British, 
and Chinese or other ethnic group, plus those with no known 
ethnicity.
We will examine information on prescriptions for any anti-
depressant within the study period, and analyse the overall 
incidence and prevalence of antidepressant prescribing by year. 
Those with a record of an antidepressant prescription before 
their study entry date will be excluded from the incidence 
cohort. We will also examine four different drug classes: selec-
tive serotonin reuptake inhibitors (SSRIs), tricyclic and related 
antidepressants (TCAs), serotonin and norepinephrine reuptake 
inhibitors (SNRIs) and other antidepressants. In addition, we 
will examine individual antidepressant drugs separately. Anti-
depressants included in the different drug classes are shown in 
table 1.
Indications recorded and whether CYP were seen by a 
secondary care specialist around the time of the first antidepres-
sant prescription will be investigated. This analysis will be limited 
to CYP who had their first antidepressant prescription in 2006–
2017. This period is after the NICE guideline for depression 
in CYP was published in 2005,11 and the quality and outcomes 
framework, which rewards general practices in the UK, intro-
duced an indicator relating to assessing severity in patients with 
a new depression diagnosis in 2006.23 Diagnostic Read codes, 
which are the standard clinical codes used in general practice 
in the UK, will be used to identify CYP with a diagnosis of 
depression, any symptoms around depression, anxiety, phobias, 
obsessive-compulsive disorder, neuropathic pain, enuresis and 
self-harm and also whether they had been referred to mental 
health services. We will use codes to identify depression diag-
noses that have been employed in previous studies.24 25 We will 
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also use F32 (depressive episode), F33 (recurrent depressive 
disorder), F40 (phobic anxiety disorders), F41 (other anxiety 
disorders), F42 (obsessive-compulsive disorder), F93.0 (sepa-
ration anxiety disorder of childhood), F93.1 (phobic anxiety 
disorder of childhood), F93.2 (social anxiety disorder of child-
hood) and X60-X84 (intentional self-harm) codes from the 
International Classification of Diseases V.10 (ICD-10) to iden-
tify indications using the linked HES datasets. We will examine 
whether there are records of these indications and of referral to 
mental health services either in the year before or up to 6 months 
after their first antidepressant prescription, apart from self-harm 
indications where we will only include those recorded up to a 
year before the first antidepressant prescription. We will examine 
the specialty of the consultant from admitted patient and outpa-
tient HES data to identify if the CYP had contact with child and 
adolescent psychiatry, forensic psychiatry, psychotherapy, adult 
mental illness, paediatrics or paediatric neurology consultants 
either in the year before or up to 6 months after their first anti-
depressant prescription.
statistical analysis
We will calculate incidence rates per 1000 person-years for 
being first prescribed an antidepressant to examine trends 
over time between 1998 and 2017 in males and females aged 
between 5 and 17 years. We will also calculate prevalence rates 
per 1000 person-years over time for people with any prescrip-
tions for antidepressants, whether these were first or subse-
quent prescriptions. These will be produced overall and for 
the separate subgroups described above. Of those who had 
been prescribed antidepressants, we will calculate the propor-
tions first prescribed different antidepressant groups and indi-
vidual drugs. Incidence rate ratios will be calculated using 
Poisson regression for the different subgroups in the different 
age and sex groups over time, clustered by GP study prac-
tice. In order to take account of varying patterns in antide-
pressant prescribing over time, linear trends will be assessed 
for different periods using piecewise linear regression26 
with change points identified by previous studies: 2002 and 
2005.8 12 Mars et al8 also identified 2008 as a change point for 
antidepressant prevalence in people aged ≥14, but not inci-
dence. We will include this too and assess its significance, as 
our study has a longer follow-up than the original analysis. 
These time points relate to different factors that were likely 
to have influenced antidepressant prescribing, particularly in 
CYP. In 2003, concerns around increased suicidal behaviour in 
association with paroxetine were raised, leading the UK medi-
cines and healthcare products regulatory agency to contraindi-
cate first paroxetine,27 then venlaflaxine28 and finally all SSRIs 
except fluoxetine29 in under 18s. Antidepressant prescriptions 
would therefore have peaked in 2002. In the UK, NICE Guide-
line CG28 on the management of depression in CYP was first 
published in 2005,11 and an update of the British Association 
for Psychopharmacology guidelines for treating depressive 
disorders with antidepressants was published in 2008.30
For people who were newly prescribed antidepressants in 
2006–2017, we will examine what proportion had received a 
diagnosis of depression, anxiety, obsessive-compulsive disorder, 
neuropathic pain or enuresis, or had symptoms of depression 
or self-harm indications recorded. We will determine what 
proportion of CYP had been seen by appropriate secondary care 
consultants between a year before and 6 months after their first 
prescription for antidepressants. We will produce these analyses 
for any antidepressant, the main antidepressant groups and the 
most commonly prescribed individual drugs. This will be done 
separately by age, sex, region, Townsend deprivation quintiles, 
and ethnic group, where numbers are sufficient.
DIsCussIon
In this study, we will examine the incidence and prevalence of 
antidepressant prescribing in CYP in England over a 20-year 
period. In order to identify inequalities, we will study variation 
in prescribing rates by region, deprivation and ethnicity. We will 
examine the indications recorded in primary care data for the 
first antidepressant prescription, and whether there is evidence 
of appointments with appropriate secondary care consultants. 
The QResearch and HES data needed for the project have already 
been collected and linked. Many of the Read code groups for 
indications have been used in previous studies, while others will 
be created and approved by the study team.
strengths and limitations
There are several strengths of our study. Examining data from a 
period of 20 years will allow long-term patterns to be assessed, 
in the context of published guidance and warnings that are likely 
to have influenced antidepressant prescribing. A large sample 
size will allow variation to be examined by region, depriva-
tion and ethnic groups, adjusted for other factors. The use of 
both primary and secondary care data will give a fuller picture 
of the indications and specialists involved in antidepressant 
prescribing in CYP. A limitation will be that we will only be able 
to examine primary care prescriptions. Any prescribing solely 
within secondary care will not be included as it is not routinely 
recorded in GP records, and it’s possible that we will therefore 
miss the true first antidepressant prescription. Only year of 
birth is recorded in QResearch to preserve anonymity. By taking 
1 January as date of birth, we will include some 4-year-olds and 
exclude some 17-year-olds from the cohort. This means our 
estimates of antidepressant prescriptions will be slight under-
estimates, as usage increases with age. It is possible that we 
will overestimate antidepressant use, as CYP may not take the 
Table 1 Antidepressants to be included in each drug class
ssrIs TCAs snrIs other
Citalopram Amitriptyline Duloxetine Agomelatine
Escitalopram Amoxapine Venlafaxine Flupentixol*
Fluoxetine Butriptyline Pristiq† Isocarboxazid
Fluvoxamine Clomipramine L-Tryptophan
Paroxetine Desipramine Mirtazapine
Sertraline Dosulepin Moclobemide
Doxepin Nefazodone
Imipramine Phenelzine
Iprindole Reboxetine
Lofepramine Tranylcypromine
Maprotiline Tryptophan
Mianserin Vortioxetine
Nortriptyline Wellbutrin†
Protriptyline
Trazodone
Trimipramine
Viloxazine
*An antipsychotic prescribed at lower doses for depressive illness in adults and the 
elderly. Therefore, only 1 mg and 500 μg tablets will be included.
†Brand name given as generic name is not included in search.
SNRIs, serotonin and norepinephrine reuptake inhibitors; SSRIs, selective serotonin 
reuptake inhibitors; TCAs,  tricyclic and related antidepressants. 
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antidepressants they were prescribed. However, we will be able 
to examine prescribing patterns, and by only assessing whether 
or not antidepressants were prescribed rather than how many 
prescriptions in the prevalence analysis, this is likely to be mini-
mised. It is expected that some records will have inaccurate or 
incomplete information recorded. By determining what propor-
tion of patients do not have appropriate information recorded, 
we will be able to evaluate the scale of these problems. This will 
highlight the need for improved recording, to ensure continuity 
of care between healthcare professionals.
ConClusIon
This study will give an up-to-date picture of antidepressant 
prescribing in CYP and whether this varies by region, depri-
vation or ethnic group. Identifying any variation will allow 
future work to focus on whether this is due to differences in 
need or practice. We will also examine primary and secondary 
care data to determine what indications are recorded asso-
ciated with initial antidepressant prescriptions, and whether 
CYP were seen by appropriate secondary care specialists. 
Understanding whether CYP are being prescribed antidepres-
sants for licensed or unlicensed indications, and whether this 
was done in partnership with secondary care specialists, will 
provide evidence of whether appropriate guidelines are being 
followed.
ethics and dissemination
The project has been reviewed in accordance with the 
QResearch agreement with East Midlands—Derby Research 
Ethics Committee [reference 18/EM/0400]. To guarantee the 
confidentiality of patient information, only the authors will 
have access to the data during the study. Two articles are 
planned to be submitted for publication from this work: (1) 
trends and variation in the incidence and prevalence of anti-
depressant prescriptions over time and (2) recording of indi-
cations and secondary care specialists seen around the time 
of first antidepressant prescription. The full statistical code 
will be available from the authors after the publication of the 
results.
Acknowledgements The authors thank patients and EMIS practices who 
contribute to the QResearch database, EMIS and the University of Nottingham 
for expertise in establishing and developing the QResearch database, and EMIS 
and the University of Oxford for its continued support and development. We also 
acknowledge that HES data used in this analysis are re-used with permission from 
NHS Digital, who retain the copyright. CH and RM are supported by the National 
Institute for Health Research (NIHR) Nottingham Biomedical Research Centre 
and NIHR MindTech MedTech Co-operative. RM is additionally supported by the 
NIHR Collaboration for Leadership in Applied Healthcare Research Collaboration 
East Midlands (CLAHRC EM). AC is supported by the National Institute for Health 
Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR 
Research Professorship (grant RP-2017-08-ST2-006) and by the NIHR Oxford Health 
Biomedical Research Centre (grant BRC-1215-20005). 
Contributors JHC had the original idea for the study. CH produced an initial draft 
of the introduction and RHJ drafted the rest of the protocol. All authors contributed 
to the development of the idea, the study design and revised the manuscript. All 
authors approved the final submitted version.
Funding The research proposed will be conducted by the National Institute of 
Health Research (NIHR) Nottingham Biomedical Research Centre Mental Health and 
Technology Theme. This work is funded by the National Institute for Health Research. 
Disclaimer NHS Digital bear no responsibility for the analysis or interpretation of 
the data. The views expressed are those of the authors and not necessarily those of 
the UK National Health Service, the NIHR or the UK Department of Health. 
Competing interests JHC is a professor of clinical epidemiology and general 
practice at the University of Oxford and co-director of QResearch®—a not-for-profit 
organisation which is a joint partnership between the University of Oxford and 
Egton Medical Information Systems (the leading commercial supplier of IT for 60% 
of general practices in the UK). JHC is also a paid director of ClinRisk Ltd which 
produces open and closed source software to ensure the reliable and updatable 
implementation of clinical risk equations within clinical computer systems to help 
improve patient care. AC is the EiC for EBMH and SC is an associate editor for EBMH. 
This work and any views expressed within it are solely those of the co-authors, and 
not of any affiliated bodies or organisations. 
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
RefeRences
 1 Sadler K, Vizard T, Ford T, et al. Mental health of children and young people in 
England, 2017 Leeds: NHS Digital, 2018.
 2 Office for National Statistics. Mid-2017 estimates of the population for the UK, 
England and Wales, Scotland and Northern Ireland. 2018 https://www. ons. gov. 
uk/ peop lepo pula tion andc ommunity/ popu lati onan dmig ration/ populationestimates/ 
datasets/ popu lati ones tima tesf oruk engl anda ndwa less cotl anda ndno rthe rnir eland 
(Accessed 29 Apr 2019).
 3 Patalay P, Fitzsimons E. Mental ill-health among children of the new century: trends 
across childhood with a focus on age 14. London: Centre for Longitudinal Studies, 
2017.
 4 Olfson M, Blanco C, Wang S, et al. National trends in the mental health care of 
children, adolescents, and adults by office-based physicians. JAMA Psychiatry 
2014;71:81–90.
 5 Thapar A, Collishaw S, Pine DS, et al. Depression in adolescence. Lancet 
2012;379:1056–67.
 6 Hopkins K, Crosland P, Elliott N, et al. Diagnosis and management of depression 
in children and young people: summary of updated NICE guidance. BMJ 
2015;350:h824.
 7 Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing 
in children and adolescents: a cohort study in The Health Improvement Network 
(THIN). PLoS One 2012;7:e33181.
 8 Mars B, Heron J, Kessler D, et al. Influences on antidepressant prescribing trends in 
the UK: 1995-2011. Soc Psychiatry Psychiatr Epidemiol 2017;52:193–200.
 9 Sarginson J, Webb RT, Stocks SJ, et al. Temporal trends in antidepressant prescribing to 
children in UK primary care, 2000-2015. J Affect Disord 2017;210:312–8.
 10 Bachmann CJ, Aagaard L, Burcu M, et al. Trends and patterns of antidepressant 
use in children and adolescents from five western countries, 2005-2012. Eur 
Neuropsychopharmacol 2016;26:411–9.
 11 National Institute for Health and Care Excellence. Depression in children and young 
people: Identification and management in primary community and secondary care 
(Clinical guideline 28). 2005 https://www. nice. org. uk/ guidance/ cg28 (Accessed 29 
Apr 2019).
 12 Wijlaars LP, Nazareth I, Whitaker HJ, et al. Suicide-related events in young people 
following prescription of SSRIs and other antidepressants: a self-controlled case series 
analysis. BMJ Open 2013;3:e003247.
 13 Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of 
antidepressants for major depressive disorder in children and adolescents: a network 
meta-analysis. Lancet 2016;388:881–90.
 14 National Institute for Health and Care Excellence. Obsessive-compulsive disorder and 
body dysmorphic disorder: treatment (Clinical guideline 31). 2005 https://www. nice. 
org. uk/ guidance/ cg31 (Accessed 29 Apr 2019).
 15 National Institute for Health and Care Excellence. Bedwetting in under 19s (Clinical 
guideline 111). 2010 https://www. nice. org. uk/ guidance/ cg111 (Accessed 29 Apr 
2019).
 16 Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, 
Pharmaceutical Press, and RCPCH Publications. http://www. medicinescomplete. com 
(Accessed 29 Apr 2019).
 17 John A, Marchant AL, Fone DL, et al. Recent trends in primary-care antidepressant 
prescribing to children and young people: an e-cohort study. Psychol Med 
2016;46:3315–27.
 18 Grigoroglou C, Munford L, Webb RT, et al. Prevalence of mental illness in primary care 
and its association with deprivation and social fragmentation at the small-area level 
in England. Psychol Med 2019:1–10.
 19 Cooper C, Spiers N, Livingston G, et al. Ethnic inequalities in the use of health 
services for common mental disorders in England. Soc Psychiatry Psychiatr Epidemiol 
2013;48:685–92.
 20 Schofield P, Das-Munshi J, Mathur R, et al. Does depression diagnosis and 
antidepressant prescribing vary by location? Analysis of ethnic density associations 
using a large primary-care dataset. Psychol Med 2016;46:1321–9.
 o
n
 4 July 2019 by guest. Protected by copyright.
http://ebm
h.bmj.com/
Evid Based M
ental Health: first published as 10.1136/ebm
ental-2019-300097 on 28 June 2019. Downloaded from
 
5Jack RH, et al. Evid Based Mental Health 2019;0:1–5. doi:10.1136/ebmental-2019-300097
Protocol
 21 Hull SA, Cornwell J, Harvey C, et al. Prescribing rates for psychotropic medication 
amongst east London general practices: low rates where Asian populations are 
greatest. Fam Pract 2001;18:167–73.
 22 Walters P, Ashworth M, Tylee A. Ethnic density, physical illness, social deprivation 
and antidepressant prescribing in primary care: ecological study. Br J Psychiatry 
2008;193:235–9.
 23 British Medical Association. Revisions to the GMS Contract, 2006/07. Delivering 
Investment in General Practice. London: BMA, 2006.
 24 Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse 
outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
 25 Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of suicide and 
attempted suicide or self harm in people aged 20 to 64: cohort study using a primary 
care database. BMJ 2015;350:h517.
 26 Gould WW. Linear splines and piecewise linear functions. Stata Technical Bulletin 
1993;15:13–17.
 27 Duff G. Safety of Seroxat (paroxetine) in children and adolescents under 18 
years - contraindication in the treatment of depressive illness. 2003 https:// 
webarchive. nationalarchives. gov. uk/ 20111114174241/ http:// www. mhra. gov. uk/ 
Safetyinformation/ Safe tywa rnin gsal erts andr ecalls/ Safe tywa rnin gsan dmes sage sfor medi 
cines/ CON2015704 (Accessed 29 Apr 2019).
 28 Duff G. Safety of venlafaxine in children and adolescents under 18 years in the 
treatment of depressive illness. 2003 https:// webarchive. nationalarchives. gov. uk/ 
20111114154314/ http:// www. mhra. gov. uk/ Safetyinformation/ Safe tywa rnin gsal erts 
andr ecalls/ Safe tywa rnin gsan dmes sage sfor medi cines/ CON2015693 (Accessed 29 Apr 
2019).
 29 Committee on Safety of Medicines. Selective Serotonin Reuptake Inhibitors (SSRIs): 
overview of regulatory status and CSM advice relating to major depressive disorder 
(MDD) in children and adolescents including a summary of available safety and 
efficacy data. 2003 https:// webarchive. nationalarchives. gov. uk/ 20150121234915/ 
http:// www. mhra. gov. uk/ Safetyinformation/ Safe tywa rnin gsal erts andr ecalls/ Safe tywa 
rnin gsan dmes sage sfor medi cines/ CON019494 (Accessed 29 Apr 2019).
 30 Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating 
depressive disorders with antidepressants: a revision of the 2000 British Association 
for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343–96.
 o
n
 4 July 2019 by guest. Protected by copyright.
http://ebm
h.bmj.com/
Evid Based M
ental Health: first published as 10.1136/ebm
ental-2019-300097 on 28 June 2019. Downloaded from
 
